“We are focused on advancing Bucillamine as a potential treatment for COVID-19, and the submission of our FDA IND application for our Phase 3 clinical study will form the foundation for our multinational clinical plans including Canada."
multinational clinical plans
The FDA submission is the base for all the other studies. We will see the Health Canada and Asian studies coming to fruition in a matter of weeks.
News 
Market Data 
Discover 
AI
